secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeyondSpring Inc. (BYSI)
CIK:        0001677940
Form:       8-K
Filed at:   2026-03-25T23:59:59+00:00
Accession:  0001171843-26-001890
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BeyondSpring reports FY2025 net loss $8.7M; Plinabulin Phase 3 survival benefit confirmed, DUBLIN-4 planned
--------------------------------------------------------------------------------

- R&D expense $4.4M, G&A $4.6M; cash $12.6M as of Dec 31, 2025.
- Plinabulin+docetaxel achieved OS HR 0.72 in non-squamous NSCLC; DUBLIN-4 confirmatory trial planned.
- SEED Therapeutics dosed first patient in Phase 1a for ST-01156; completed $30M Series A-3 financing.
- Sold portion of SEED preferred shares for ~$35.4M gross proceeds; first closing $7.35M in Feb 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1677940/000117184326001890/0001171843-26-001890-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1677940/000117184326001890/f8k_032526.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-001890

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer